Filing Flows › Roivant Sciences (ROIV) › Q1 FY27
Roivant Sciences (ROIV) Q1 FY27 earnings results (first quarter fiscal 2027)
10-Q filed Aug 6, 2026
Roivant Sciences (ROIV) reported revenue of $1.4M for the first quarter fiscal 2027 (Q1 FY27), -34% from a year earlier and -43% from the quarter before.
Roivant Sciences, Q1 FY27: revenue $1.4M (-34% year over year), net loss $291M, operating cash flow −$271M. The chart follows the revenue to costs, profit and cash.
| Q1 FY27 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.4M | -43% | -34% |
| Operating profit | −$366M | -188% | — |
| Net earnings | −$291M | -196% | — |
| Operating cash flow | −$271M | — | — |
What changed
Revenue was $1.4M in Q1 FY27, down 34% year over year and down 43% from the previous quarter.
Operating costs exceeded revenue by $366.0M, an operating margin of -25380.9%. Total costs grew 28% against a revenue fall of 34%. The fastest-growing cost line was Research & development (+32%). The quarter ended with a net loss of $290.6M, after a profit of $355.7M the previous quarter. Minority interests bore $100.8M of it: to shareholders the quarter was a loss of $189.8M. Non-operating items added $71.4M, -24% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$270.5M. Non-cash charges added back $600K of depreciation and amortization and $83.3M of share-based compensation. Working capital and other items used $63.8M. Capital expenditures of $419K exceeded it, leaving free cash flow of −$270.9M.
Questions
What was Roivant Sciences' revenue in the first quarter fiscal 2027?
Roivant Sciences (ROIV) reported revenue of $1.4M for the first quarter fiscal 2027 (Q1 FY27), -34% from a year earlier and -43% from the quarter before.
Source: Roivant Sciences 10-Q on SEC EDGAR.